NEOGENOMICS INC — Form 8-K
Filed October 28, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
NeoGenomics reported Q3 2026 revenue of $209M (+11% YoY), with clinical revenue up 13% driven by NGS growth of 29%. The company raised FY2026 guidance to $807–809M revenue (from $806M high) and ~$60M adjusted EBITDA (from $58M). Net loss improved 72% to $8M, adjusted EBITDA rose 53% to $19M. CEO Tony Zook will become Executive Chairman on January 4, 2027; COO Warren Stone becomes CEO. Medicare expanded RaDaR ST coverage to immunotherapy monitoring. Cash was $139M; convertible debt increased to $375M.
Why this rating
Strong operational momentum (NGS +29%, margin expansion +310 bps) and guidance raise are positive. Leadership transition and modest debt increase are neutral-to-cautionary. Event is ~15% of market cap; material but not transformational.
See more from October 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.